Elastic-to-plastic crossover below the peak effect in the vortex solid of YBa2Cu3O7 single crystals

We report on transport and ac susceptibility studies below the peak effect in twinned YBa2Cu3O7 single crystals. We find that disorder generated at the peak effect can be partially inhibited by forcing vortices to move with an ac driving current. The vortex system can be additionally ordered below a well-defined temperature where elastic interactions between vortices overcome pinning-generated stress and a plastic to elastic crossover seems to occur. The combined effect of these two processes results in vortex structures with different mobilities that give place to history effects.Comment: 4 pages, 4 figures. Published in PRB Rapid Comm., February 1, 200

Baryogenesis vs. proton stability in theories with extra dimensions

We propose a new scenario of baryogenesis in the context of theories with large extra dimensions. The baryon number is almost conserved at zero temperature by means of a localization mechanism recently analyzed by Arkani-Hamed and Schmaltz: leptons and quarks are located at two slightly displaced positions in the extra space, and this naturally suppresses the interactions which ``convert'' the latter in the former. We show that this is expected to be no longer true when finite temperature effects are taken into account. The whole scenario is first presented in its generality, without referring to the bulk geometry or to the specific mechanism which may generate the baryon asymmetry. As an example, we then focus on a baryogenesis model reminiscent of GUT baryogenesis. The Sakharov out of equilibrium condition is satisfied by assuming nonthermal production of the bosons that induce baryon number violation.Comment: 10 pages, 1 figur

Super-acceleration on the Brane by Energy Flow from the Bulk

We consider a brane cosmological model with energy exchange between brane and bulk. Parameterizing the energy exchange term by the scale factor and Hubble parameter, we are able to exactly solve the modified Friedmann equation on the brane. In this model, the equation of state for the effective dark energy has a transition behavior changing from $w_{de}^{eff}>-1$ to $w_{de}^{eff}<-1$, while the equation of state for the dark energy on the brane has $w>-1$. Fitting data from type Ia supernova, Sloan Digital Sky Survey and Wilkinson Microwave Anisotropy Probe, our universe is predicted now in the state of super-acceleration with $w_{de0}^{eff}=-1.21$.Comment: Revtex, 11 pages including 2 figures,v2: tpos fixed, references added, to appear in JCA

Dynamical Lorentz simmetry breaking from 3+1 Axion-Wess-Zumino model

We study the renormalizable abelian vector-field models in the presence of the Wess-Zumino interaction with the pseudoscalar matter. The renormalizability is achieved by supplementing the standard kinetic term of vector fields with higher derivatives. The appearance of fourth power of momentum in the vector-field propagator leads to the super-renormalizable theory in which the $\beta$-function, the vector-field renormalization constant and the anomalous mass dimension are calculated exactly. It is shown that this model has the infrared stable fixed point and its low-energy limit is non-trivial. The modified effective potential for the pseudoscalar matter leads to the possible occurrence of dynamical breaking of the Lorentz symmetry. This phenomenon is related to the modification of Electrodynamics by means of the Chern-Simons (CS) interaction polarized along a constant CS vector. Its presence makes the vacuum optically active that has been recently estimated from astrophysical data. We examine two possibilities for the CS vector to be time-like or space-like, under the assumption that it originates from v.e.v. of some pseudoscalar matter and show that only the latter one is consistent in the framework of the AWZ model, because a time-like CS vector makes the vacuum unstable under pairs creation of tachyonic photon modes with the finite vacuum decay rate.Comment: 33 pages, no Figures, Plain TeX, submitted to Phys. Rev.

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

BACKGROUND Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizu- mab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in patients with severe Covid-19 pneumonia in case reports and retrospective observational cohort studies. Data are needed from randomized, placebo-controlled trials. METHODS In this phase 3 trial, we randomly assigned patients who were hospitalized with severe Covid-19 pneumonia in a 2:1 ratio receive a single intravenous infusion of tocilizumab (at a dose of 8 mg per kilogram of body weight) or placebo. Approxi- mately one quarter of the participants received a second dose of tocilizumab or placebo 8 to 24 hours after the first dose. The primary outcome was clinical status at day 28 on an ordinal scale ranging from 1 (discharged or ready for discharge) to 7 (death) in the modified intention-to-treat population, which included all the patients who had received at least one dose of tocilizumab or placebo. RESULTS Of the 452 patients who underwent randomization, 438 (294 in the tocilizumab group and 144 in the placebo group) were included in the primary and secondary analyses. The median value for clinical status on the ordinal scale at day 28 was 1.0 (95% confidence interval [CI], 1.0 to 1.0) in the tocilizumab group and 2.0 (non-ICU hospitalization without supplemental oxygen) (95% CI, 1.0 to 4.0) in the placebo group (between-group difference, −1.0; 95% CI, −2.5 to 0; P=0.31 by the van Elteren test). In the safety population, serious adverse events occurred in 103 of 295 patients (34.9%) in the tocilizumab group and in 55 of 143 patients (38.5%) in the placebo group. Mortality at day 28 was 19.7% in the tocilizumab group and 19.4% in the placebo group (weighted difference, 0.3 percentage points (95% CI, –7.6 to 8.2; nominal P=0.94). CONCLUSIONS In this randomized trial involving hospitalized patients with severe Covid-19 pneu- monia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days. (Funded by F. Hoffmann–La Roche and the Department of Health and Human Services; COVACTA ClinicalTrials.gov num- ber, NCT04320615.

What does inflation really predict?

If the inflaton potential has multiple minima, as may be expected in, e.g., the string theory "landscape", inflation predicts a probability distribution for the cosmological parameters describing spatial curvature (Omega_tot), dark energy (rho_Lambda, w, etc.), the primordial density fluctuations (Omega_tot, dark energy (rho_Lambda, w, etc.). We compute this multivariate probability distribution for various classes of single-field slow-roll models, exploring its dependence on the characteristic inflationary energy scales, the shape of the potential V and and the choice of measure underlying the calculation. We find that unless the characteristic scale Delta-phi on which V varies happens to be near the Planck scale, the only aspect of V that matters observationally is the statistical distribution of its peaks and troughs. For all energy scales and plausible measures considered, we obtain the predictions Omega_tot ~ 1+-0.00001, w=-1 and rho_Lambda in the observed ballpark but uncomfortably high. The high energy limit predicts n_s ~ 0.96, dn_s/dlnk ~ -0.0006, r ~ 0.15 and n_t ~ -0.02, consistent with observational data and indistinguishable from eternal phi^2-inflation. The low-energy limit predicts 5 parameters but prefers larger Q and redder n_s than observed. We discuss the coolness problem, the smoothness problem and the pothole paradox, which severely limit the viable class of models and measures. Our findings bode well for detecting an inflationary gravitational wave signature with future CMB polarization experiments, with the arguably best-motivated single-field models favoring the detectable level r ~ 0.03. (Abridged)Comment: Replaced to match accepted JCAP version. Improved discussion, references. 42 pages, 17 fig

Use of Lichen and Moss in Assessment of Forest Contamination with Heavy Metals in Praded and Glacensis Euroregions (Poland and Czech Republic)

The concentrations of selected metals—Cr, Ni, Cu, Zn, Cd, and Pb—were determined in the samples of Hypogymnia physodes lichen and Pleurozium schreberi moss collected in Polish and Czech Euroregions Praded and Glacensis. More specifically, the samples were collected in Bory Stobrawskie, Bory Niemodlińskie, and Kotlina Kłodzka (Poland) and in Jeseniki (Czech Republic). The concentration of metals in the samples was measured using the atomic absorption spectrometry (flame AAS technique and electrothermal atomization AAS technique). The results were used to calculate the comparison factor (CF) that quantifies the difference in concentration of a given bioavailable analyte × accumulated in lichens and mosses: CF = 2 (cx,lichen − cx,moss) (cx,lichen + cx,moss)−1. The values of CF greater than 0.62 indicate the most probable location of heavy metals deposited in the considered area. In this work, the method was used to show a significant contribution of urban emissions to the deposition of heavy metals in the area of Bory Stobrawskie and in the vicinity of Kłodzko City

Accidental Inflation in String Theory

We show that inflation in type IIB string theory driven by the volume modulus can be realized in the context of the racetrack-based Kallosh-Linde model (KL) of moduli stabilization. Inflation here arises through the volume modulus slow-rolling down from a flat hill-top or inflection point of the scalar potential. This situation can be quite generic in the landscape, where by uplifting one of the two adjacent minima one can turn the barrier either to a flat saddle point or to an inflection point supporting eternal inflation. The resulting spectral index is tunable in the range of 0.93 < n_s < 1, and there is only negligible production of primordial gravitational waves r < 10^{-6}. The flatness of the potential in this scenario requires fine-tuning, which may be justified taking into account the exponential reward by volume factors preferring the regions of the universe with the maximal amount of slow-roll inflation. This consideration leads to a tentative prediction of the spectral index $n_s\approx 0.95$ or $n_s \approx 0.93$ depending on whether the potential has a symmetry phi -> - phi or not.Comment: 15 pages, 6 figures, LaTeX, uses RevTex

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia

BACKGROUND Coronavirus disease 2019 (Covid-19) is associated with immune dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of tocilizumab, a monoclonal antibody against the interleukin-6 receptor, has resulted in better outcomes in patients with severe Covid-19 pneumonia in case reports and retrospective observational cohort studies. Data are needed from randomized, placebo-controlled trials. METHODS In this phase 3 trial, we randomly assigned patients who were hospitalized with severe Covid-19 pneumonia in a 2:1 ratio receive a single intravenous infusion of tocilizumab (at a dose of 8 mg per kilogram of body weight) or placebo. Approximately one quarter of the participants received a second dose of tocilizumab or placebo 8 to 24 hours after the first dose. The primary outcome was clinical status at day 28 on an ordinal scale ranging from 1 (discharged or ready for discharge) to 7 (death) in the modified intention-to-treat population, which included all the patients who had received at least one dose of tocilizumab or placebo. RESULTS Of the 452 patients who underwent randomization, 438 (294 in the tocilizumab group and 144 in the placebo group) were included in the primary and secondary analyses. The median value for clinical status on the ordinal scale at day 28 was 1.0 (95% confidence interval [CI], 1.0 to 1.0) in the tocilizumab group and 2.0 (non-ICU hospitalization without supplemental oxygen) (95% CI, 1.0 to 4.0) in the placebo group (between-group difference, −1.0; 95% CI, −2.5 to 0; P=0.31 by the van Elteren test). In the safety population, serious adverse events occurred in 103 of 295 patients (34.9%) in the tocilizumab group and in 55 of 143 patients (38.5%) in the placebo group. Mortality at day 28 was 19.7% in the tocilizumab group and 19.4% in the placebo group (weighted difference, 0.3 percentage points; 95% CI, –7.6 to 8.2; nominal P=0.94). CONCLUSIONS In this randomized trial involving hospitalized patients with severe Covid-19 pneumonia, the use of tocilizumab did not result in significantly better clinical status or lower mortality than placebo at 28 days. (Funded by F. Hoffmann–La Roche and the Department of Health and Human Services; COVACTA ClinicalTrials.gov number, NCT04320615